Effects of Combination Therapy with Celecoxib and Doxycycline on Neointimal Hyperplasia and Inflammatory Biomarkers in Coronary Artery Disease Patients Treated with Bare Metal Stents
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-9 play a key role in the pathogenesis of in-stent restenosis. We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia. Materials and Methods: A total of 75 patients (86 lesions) treated with bare metal stents were randomized into three groups: 1) combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily), 2) celecoxib (200 mg twice daily) only, and 3) non-therapy control. Celecoxib and doxycycline were administered for 3 weeks after coronary stenting. The primary endpoint was neointimal volume obstruction by intravascular ultrasound (IVUS) at 6 months. The secondary endpoints included clinical outcomes, angiographic data, and changes in blood levels of inflammatory biomarkers. Results: Follow-up IVUS revealed no significant difference in the neointimal volume obstruction among the three treatment groups. There was no difference in cardiac deaths, myocardial infarctions, target lesion revascularization or stent thrombosis among the groups. Blood levels of high-sensitivity C-reactive protein, soluble CD40 ligand, and MMP-9 varied widely 48 hours and 3 weeks after coronary stenting, however, they did not show any significant difference among the groups. Conclusion: Our study failed to demonstrate any beneficial effects of the short-term therapy with celecoxib and doxycycline or with celecoxib alone in the suppression of inflammatory biomarkers or in the inhibition of neointimal hyperplasia. Large scale randomized trials are necessary to define the role of anti-inflammatory therapy in the inhibition of neointimal hyperplasia.
Abstract
Purpose: Cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-9 play a key role in the pathogenesis of in-stent restenosis. We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia. Materials and Methods: A total of 75 patients (86 lesions) treated with bare metal stents were randomized into three groups: 1) combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily), 2) celecoxib (200 mg twice daily) only, and 3) non-therapy control. Celecoxib and doxycycline were administered for 3 weeks after coronary stenting. The primary endpoint was neointimal volume obstruction by intravascular ultrasound (IVUS) at 6 months. The secondary endpoints included clinical outcomes, angiographic data, and changes in blood levels of inflammatory biomarkers. Results: Follow-up IVUS revealed no significant difference in the neointimal volume obstruction among the three treatment groups. There was no difference in cardiac deaths, myocardial infarctions, target lesion revascularization or stent thrombosis among the groups. Blood levels of high-sensitivity C-reactive protein, soluble CD40 ligand, and MMP-9 varied widely 48 hours and 3 weeks after coronary stenting, however, they did not show any significant difference among the groups. Conclusion: Our study failed to demonstrate any beneficial effects of the short-term therapy with celecoxib and doxycycline or with celecoxib alone in the suppression of inflammatory biomarkers or in the inhibition of neointimal hyperplasia. Large scale randomized trials are necessary to define the role of anti-inflammatory therapy in the inhibition of neointimal hyperplasia.
참고문헌 (21)
- Welt FG, "Inflammation and restenosis in the stent era", Arterioscler Thromb Vasc Biol, 22, pp.1769~1776 (2002)
- Farb A, "Morphological predictors of restenosis after coronary stenting in humans", Circulation, 105, pp.2974~2980 (2002)
- McAdam BF, "Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2", Proc Natl Acad Sci U S A, 96, pp.272~277 (1999)
- Schönbeck U, "Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions", Am J Pathol, 155, pp.1281~1291 (1999)
- Dollery CM, "Matrix metalloproteinases and cardiovascular disease", Circ Res, 77, pp.863~868 (1995)
- Bendeck MP, "Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury", Circ Res, 78, pp.38~43 (1996)
- Connolly E, "Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty", J Pharmacol Exp Ther, 300, pp.393~398 (2002)
- Wang K, "Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model", J Cardiovasc Pharmacol, 45, pp.61~67 (2005)
- 윤석원, "Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling", CIRCULATION, 110, pp.301~308, LIPPINCOTT WILLIAMS & WILKINS
- Koo BK, "Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study", Lancet, 370, pp.567~574 (2007)
- Bresalier RS, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial", N Engl J Med, 352, pp.1092~1102 (2005)
- Graham DJ, "Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study", Lancet, 365, pp.475~481 (2005)
- Bendeck MP, "Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury", Am J Pathol, 160, pp.1089~1095 (2002)
- Serruys PW, "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group", N Engl J Med, 331, pp.489~495 (1994)
- Fischman DL, "A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators", N Engl J Med, 331, pp.496~501 (1994)
- Solinas E, "Gender-specific outcomes after sirolimus-eluting stent implantation", J Am Coll Cardiol, 50, pp.2111~2116 (2007)
- Bogaty P, "Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study", Circulation, 110, pp.934~939 (2004)
- Title LM, "Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease", J Am Coll Cardiol, 42, pp.1747~1753 (2003)
- Chenevard R, "Selective COX-2 inhibition improves endothelial function in coronary artery disease", Circulation, 107, pp.405~409 (2003)
- Niederberger E, "Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells", Biochem Pharmacol, 68, pp.341~350 (2004)
- Walter MF, "Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs", Atherosclerosis, 177, pp.235~243 (2004)